SLXN has 36-month beta value of -0.02. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLXN is 1.02M, and currently, short sellers hold a 19.86% ratio of that float. The average trading volume of SLXN on January 01, 2025 was 891.65K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SLXN) stock’s latest price update
Silexion Therapeutics Corp (NASDAQ: SLXN) has experienced a decline in its stock price by -11.45 compared to its previous closing price of 2.27. However, the company has seen a fall of -20.55% in its stock price over the last five trading days. businesswire.com reported 2024-12-17 that LONDON–(BUSINESS WIRE)—- $AMGN #biotech–PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the most dynamic areas of cancer treatment innovation. Among the key players pioneering novel approaches is Silexion Therapeutics, a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven cancers—one of the most prevalent and historically “undruggable” oncogenic drivers. Silexion’.
SLXN’s Market Performance
SLXN’s stock has fallen by -20.55% in the past week, with a monthly drop of -27.96% and a quarterly drop of -59.85%. The volatility ratio for the week is 18.38% while the volatility levels for the last 30 days are 19.96% for Silexion Therapeutics Corp The simple moving average for the past 20 days is -25.69% for SLXN’s stock, with a -96.33% simple moving average for the past 200 days.
SLXN Trading at -23.84% from the 50-Day Moving Average
After a stumble in the market that brought SLXN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.35% of loss for the given period.
Volatility was left at 19.96%, however, over the last 30 days, the volatility rate increased by 18.38%, as shares sank -35.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.48% lower at present.
During the last 5 trading sessions, SLXN fell by -20.55%, in comparison to the 20-day moving average, which settled at $2.70. In addition, Silexion Therapeutics Corp saw -97.94% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLXN
Equity return is now at value -3.78, with -284.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.85.
Conclusion
To put it simply, Silexion Therapeutics Corp (SLXN) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
